24. April 2017

Abstract Reducing the promiscuous tropism of native adenovirus by using fiberless adenovirus is advantageous towards its use as a gene therapy vector or vaccine component. The removal of the fiber protein on native adenovirus abrogates several undesirable interactions; however, this approach decreases the particle’s physical stability. In order to create stable fiberless adenovirus for pharmaceutical use, the effects of temperature and pH on the particle’s stability profile must be...

25. June 2016

Abstract Background Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). Objective To develop simplified entecavir dosing recommendations for young children infected with CHB. Methods Data from recent clinical trials were used to develop a population pharmacokinetic (PPK) model, which allowed us to...

01. May 2016

We have produced a thermally stable recombinant human type 5 adenoviral vector (AdHu5) through spray drying with three excipient formulations (l-leucine, lactose/trehalose and mannitol/dextran). Spray drying leads to immobilization of the viral vector which is believed to prevent viral protein unfolding, aggregation and inactivation. The spray dried powders were characterized by scanning electron microscopy, differential scanning calorimetry, Karl Fischer titrations, and X-ray diffraction to...